Video

Aurion BioTech presents cell therapy findings with published clinical data

Author(s):

Kassi Filkins
Conferences|ASCRS

Greg Kunst, president and CEO of Aurion BioTech, shares a company update on endothelial cell therapy trials, clinical plans and upcoming data.

Related Videos
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
Related Content
(Image credit: AdobeStock/Atif)
March 21st 2025

Staying the course in shifting winds

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: AdobeStock/©KayExam/peopleimages.com)
March 10th 2025

A new era for MacTel: Clinicians react to FDA approval of revakinagene taroretcel-lwey

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Ocular clues aid in identifying neuromyelitis optica spectrum disorder
March 7th 2025

Ocular clues aid in identifying neuromyelitis optica spectrum disorder

FDA approves revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2
March 6th 2025

FDA approves revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2

© 2025 MJH Life Sciences

All rights reserved.